Arbutus Biopharma (Arbutus Biopharma) Operating Cash Flow per Share : $-0.52 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Operating Cash Flow per Share?

Arbutus Biopharma's operating cash flow per share for the three months ended in Dec. 2023 was $-0.10. Arbutus Biopharma's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.52.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 8.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 23.50% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Arbutus Biopharma's Operating Cash Flow per Share or its related term are showing as below:

ABUS' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -35.3 Med: 8.6 Max: 43.9
Current: 8.6

During the past 13 years, Arbutus Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 43.90% per year. The lowest was -35.30% per year. And the median was 8.60% per year.

ABUS's 3-Year OCF Growth Rate is ranked better than
54.99% of 1242 companies
in the Biotechnology industry
Industry Median: 3.6 vs ABUS: 8.60

Arbutus Biopharma Operating Cash Flow per Share Historical Data

The historical data trend for Arbutus Biopharma's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Operating Cash Flow per Share Chart

Arbutus Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.24

-0.68

-0.64

-0.23

-0.52

Arbutus Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.11	-0.17	-0.12	-0.13	-0.10

Competitive Comparison of Arbutus Biopharma's Operating Cash Flow per Share

For the Biotechnology subindustry, Arbutus Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Price-to-Operating-Cash-Flow falls into.

Arbutus Biopharma Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Arbutus Biopharma's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-85.936	/	165.960
	=	-0.52

Arbutus Biopharma's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-17.292	/	168.586
	=	-0.10

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52

Arbutus Biopharma Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma (Arbutus Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Executives

Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims	officer: Chief Medical Officer	701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger	officer: General Counsel and CCO	633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia	officer: Chief Scientific Officer	C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran	director	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh	officer: Chief Business Officer	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers	director	GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng	director	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier	director, officer: President and CEO	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard	officer: Executive VP & General Counsel	100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings	officer: Chief Financial Officer	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio	officer: Chief Development Officer	C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8